Avenue Therapeutics Announces FDA Advisory Committee Meeting to Review IV Tramadol NDA Tentatively Scheduled for February 15, 2022

Nov 29, 2021

Journey Medical Corporation Introduces Expanded Board of Directors

Nov 29, 2021

Avenue Therapeutics Announces Exercise and Closing of Underwriter’s Over-Allotment Option

Nov 17, 2021

Journey Medical Corporation Announces Closing of Initial Public Offering

Nov 16, 2021

Fortress Biotech Reports Record Third Quarter 2021 Financial Results and Recent Corporate Highlights

Nov 15, 2021

Avenue Therapeutics Announces Closing of Public Offering of Common Stock

Nov 12, 2021

Mustang Bio Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights

Nov 12, 2021

Journey Medical Corporation Prices $35.2 Million Initial Public Offering

Nov 12, 2021

Mustang Bio Announces Exclusive Worldwide License Agreement with Leiden University Medical Centre for Clinical-Stage Lentiviral Gene Therapy with Curative Potential for RAG1 Severe Combined Immunodeficiency

Nov 10, 2021

Avenue Therapeutics Prices $2.6 Million Underwritten Public Offering of Common Stock

Nov 09, 2021